NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Comments on twitter from Craig Horbinski on:
"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG / NOA-09): a randomized, open-label, phase 3 trial."

A key to the potential success of this trial (Sean's wise observations taken into consideration) was the fact that they combined two cytotoxic drugs AT THE TIME OF INITIAL DIAGNOSIS. Hit 'em as hard as possible upfront!

https://pbs.twimg.com/media/DztF0PYXgAoI3x4.png
https://pbs.twimg.com/media/DztGdowXcAAiMTy.png

Craig Horbinski @CraigHorbinski

I am a molecular #neuropathologist at #Northwestern University who specializes in #braintumor research. My #NIH-funded laboratory studies IDH1 mutant #gliomas.